A retrospective study published in Breast Cancer Research and Treatment followed 284 women with node-positive breast cancer who received neoadjuvant chemotherapy, the chemotherapy administered before surgery with the goal of shrinking tumors and, in some patients, eradicating nodal disease entirely. The analysis, conducted by a team at the University of Pittsburgh led by Callie Hlavin and Emilia J. Diego, compared patients who underwent full axillary lymph node dissection with those who received targeted axillary dissection, a deliberately limited procedure that removes only the previously involved, marked lymph node along with nearby sentinel nodes. With a median follow-up of 36.3 months, the researchers found no meaningful difference in recurrence, mortality, disease-free survival, or overall survival between the two operations in either of the clinical groups they examined.

The study exploited a technical innovation that has reshaped how surgeons think about the axilla after neoadjuvant chemotherapy. Before treatment begins, the biopsy-proven cancerous lymph node is marked — in this study, with a radioactive iodine seed — so that the same node can be identified and removed after chemotherapy, even if the tumor inside it has completely disappeared. This approach, known as targeted axillary dissection or TAD, allows surgeons to re-examine the very node that harbored cancer at diagnosis, dramatically reducing the false-negative rate compared with sentinel lymph node biopsy alone. After surgery, patients are divided into two groups based on what pathologists find in that recovered node: those with a complete pathologic response, meaning the diseased node shows no residual cancer, and those with persistent disease.

Of the 284 patients, 128 achieved a complete pathologic response in the marked node, designated dSLN-negative. Only 13 of these women went on to receive a full axillary dissection, while 115 — roughly 90 percent — were managed with targeted axillary dissection alone. The remaining 156 patients still had cancer in the marked node after chemotherapy, designated dSLN-positive; 107 of them underwent full axillary lymph node dissection and 49 received targeted dissection. This distribution reflects an evolving practice pattern in which surgeons increasingly feel comfortable omitting the full dissection when the marked node shows eradication of disease, and the Pittsburgh data now provide some of the most direct evidence yet that this comfort is justified.

The survival figures are striking for their equivalence. Among patients with a complete response in the marked node, mortality was 15.4 percent after full axillary dissection versus 8.9 percent after targeted dissection, a difference that did not approach statistical significance. Disease-free survival averaged 19.6 months in the dissection group and 30.7 months in the targeted group, and overall survival was 49.3 versus 45.8 months — again, without significant differences. Among patients with persistent disease in the marked node, mortality was 9.3 percent with targeted surgery versus 10.2 percent with full dissection, disease-free survival was 30 versus 37 months, and overall survival was nearly identical at 36.4 versus 36.2 months. Across every measure the investigators tracked — frequency of recurrence, location of recurrence, death, disease-free survival, and overall survival — the extent of axillary surgery made no difference.

One nuance deserves attention. In the group with persistent nodal disease, the researchers observed a higher frequency of recurrence among patients who underwent full axillary lymph node dissection compared with those who had targeted dissection. That finding runs counter to the traditional assumption that removing more nodes always confers better local control, though the investigators caution that it did not translate into any difference in disease-free or overall survival, and the retrospective design and modest subgroup sizes limit how much weight the observation can bear. What it does underscore is the central paradox that has driven the de-escalation movement: decades of trials have shown that additional axillary surgery does not reliably improve survival, even when it changes local recurrence patterns.

The scientific rationale for trimming axillary surgery rests on biology as much as surgical outcomes. Neoadjuvant chemotherapy can completely eradicate nodal metastases in a substantial fraction of node-positive patients, and that pathologic response is among the most powerful prognostic markers in breast cancer. Systemic therapy circulating throughout the body treats microscopic disease wherever it resides, while regional nodal surgery mainly serves staging and local control. Landmark trials such as ACOSOG Z0011 demonstrated that omitting full dissection in selected sentinel-node-positive patients did not compromise survival, and studies including ACOSOG Z1071, SENTINA, and SN FNAC established that sentinel node biopsy after neoadjuvant chemotherapy is technically feasible — provided the previously positive node itself is identified and removed, which is precisely what radioactive seed marking and targeted dissection accomplish.

The stakes of this debate are far from academic. Axillary lymph node dissection removes a large volume of lymphatic tissue and is a leading cause of lymphedema, the chronic, sometimes disabling swelling of the arm that can follow breast cancer treatment. It is also associated with shoulder stiffness and reduced range of motion, numbness, pain syndromes, infection, and longer operative times and hospital stays. Prospective studies following patients for years after surgery have documented persistent deficits in shoulder strength and function in women who undergo the full dissection compared with those who receive sentinel biopsy alone. If equivalent survival can be achieved without those complications, the argument for routine full dissection in chemotherapy responders weakens considerably — and the Pittsburgh data suggest that even some patients with residual disease in the marked node may fare just as well with less surgery when combined with appropriate radiation and systemic therapy.

The findings arrive amid an active international effort to define exactly how far axillary de-escalation can safely go. Ongoing randomized trials, including TAXIS and the AXSANA study, are comparing less invasive nodal procedures with standard approaches in patients whose disease converts from node-positive to node-negative after chemotherapy. Practice guidelines, including those from the National Comprehensive Cancer Network, have gradually incorporated the option of omitting full dissection for selected patients with a complete response, and surveys of breast surgeons show rapidly shifting practice patterns. The present study adds real-world evidence to this landscape: in a consecutive cohort treated at a single academic center, the extent of axillary surgery simply did not determine who recurred, who survived, or how long they lived free of disease.

Important limitations temper the conclusions. The analysis was retrospective and single-institution, meaning treatment decisions were not randomized and selection bias may have influenced which patients received which operation — indeed, patients with persistent disease were far more likely to undergo full dissection, likely reflecting surgeon and patient preference for maximal treatment. The follow-up of just over three years is meaningful but not definitive for breast cancer, whose recurrences can appear a decade or more after diagnosis, and the small numbers of full dissections among patients with complete response limit statistical power. Nevertheless, the consistency of the results across both patient groups, and their alignment with randomized trial evidence accumulated over the past two decades, makes a compelling case. For the growing number of women whose lymph node disease melts away with preoperative chemotherapy, the message is increasingly clear: the most extensive operation is not the one that saves lives, and a carefully targeted, node-by-node approach may offer the same survival with a fraction of the harm.

Subject of Research: Comparison of targeted axillary dissection versus axillary lymph node dissection for survival outcomes in node-positive breast cancer patients receiving neoadjuvant chemotherapy

Article Title: Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy

Article References: Hlavin, C., Balogun, Z., Lavage, D. R., Cowher, M. S., Lupinacci, K., Sabih, Q., Soran, A., Steiman, J. G., McAuliffe, P. F., & Diego, E. J. (2026). Equivalent survival in targeted axillary dissection compared to axillary lymph node dissection in patients with node positive breast cancer receiving neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 219(3), Article 18. https://doi.org/10.1007/s10549-026-08078-1

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08078-1

Keywords: breast cancer, neoadjuvant chemotherapy, targeted axillary dissection, axillary lymph node dissection, sentinel lymph node biopsy, axillary de-escalation, lymphedema, disease-free survival, overall survival, pathologic complete response, radioactive seed localization, surgical oncology